PYNGF Pyng Medical Corp featured news, full reports, and detailed charts
Pyng Medical Corp (PYNGF/PYNGF.PK) Wrap Up:
Pyng Medical Corp. engages in the production and sale of the emergency medical systems. The company offers FAST1, which is an intraosseous infusion system that provides lifesaving vascular access for fluid and drug resuscitation in shock and trauma victims. Its customers include military medics, civilian paramedics, physicians, physician assistants, and nurses at the scene of medical emergencies, in ambulances, on board emergency medical aircrafts, in hospital emergency departments or on hospital ‘CRASH’ carts. The company sells its FAST1 products in the United States and Europe through distributors, and has approval to sell these products in Canada, Australia, South Africa, and Asia. Pyng M...Pyng Medical Corp (PYNGF:OTC)
|
Market Cap
2.5M
|
Total Revenue
6.5M
|
|
|
EBITDA
687.4K
|
DILUTED EPS TTM
-0.02
|
|
|
P/E
--
|
P/S
0.4x
|
|
|
Return On Asset
2.33
|
Return On Equity
-5.83
|
|
| K = Thousands M = Millions B = Billions | ||
PYNGF Top Compensated Officers
Executives, Board Directors
Key developments for Pyng Medical Corp (PYNGF)
Pyng Medical Corp. reported that Steve Law has resigned from the positions of Chief Financial Officer and Corporate Secretary of the company. Mr. Law will continue to work with the board and senior management in support of a smooth transition while he pursues other business interests. The company is in the process of searching for new candidates for the positions of Chief Financial Officer and Corporate Secretary. Until a proper replacement for Mr. Law is obtained, the company's current President and Chief Executive Officer, Robert Di Silvio, will act as the company's Chief Financial Officer for a temporary period.
Pyng Medical Corp. announced that an exclusive prime vendor agreement was signed with Tri-anim Health Services Inc. (Sarnova LLC) to extend the company's products into the hospital market. Tri-anim Health Services will exclusively distribute the FAST1® Intraosseous Infusion System for IO procedures and the T-POD® Pelvic Stabilizer to various hospital facilities within the US.
Pyng Medical Corp. reported consolidated earnings results for the third quarter and nine months ended June 30, 2009. For the quarter, the company reported net loss of CAD 101,518 or CAD 0.01 per diluted share on sales of CAD 1,288,743 compared to net income of CAD 95,573 or CAD 0.01 per diluted share on sales of CAD 1,624,967 for the same period in 2008. Cash flow from operating activities for the quarter was CAD 415,170 compared to CAD 153,993 for the same period a year ago. Acquisition of property, plant and equipment for the quarter was CAD 8,136 compared to CAD 7,301 for the same period in 2008. For the nine months ended June 30, 2009, the company reported net loss of CAD 285,433 or CAD 0.02 per diluted share on sales of CAD 4,307,905 compared to net income of CAD 293,414 or CAD 0.03 per diluted share on sales of CAD 4,380,943 for the same period in 2008. Cash flow used in operating activities for the period was CAD 457,132 compared to CAD 480,896 for the same period a year ago. Acquisition of property, plant and equipment for the period was CAD 110,590 compared to CAD 19,941 for the same period in 2008.
PYNGF Competitors
| Company | Last | Change | |
| No competitor information is available for PYNGF. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | PYNGF | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.4x |
|
| Price/Book | 0.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.3x |
|
|
PYNGF |
||
PYNGF transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||